Cenexi in the news

Gland Pharma reports a strong turnaround in its Cenexi operations with a robust core business and new product launches contributing to growth.

Gland Pharma reports record financial performance driven by its CDMO segment and the recovery of its Cenexi acquisition.

Cenexi employees in Fontenay-sous-Bois strike for higher wages and improved working conditions during salary negotiations.

Gland Pharma's Q3 FY26 results show strong revenue and profitability growth, with Cenexi turning profitable and major capex planned to expand CDMO and specialty injectable capacities.

Gland Pharma's Q3 FY26 results showed strong growth led by its French subsidiary Cenexi reaching breakeven, but valuation concerns and market pressures remain key challenges.

Gland Pharma's quarterly profit rose 12% as its European drug manufacturing unit, Cenexi, recovered from production issues to boost margins.

Gland Pharma's Q2 profit rose 12% aided by a strong recovery at its European drug manufacturing unit Cenexi, boosting margins and sales.

Cenexi's turnaround is helping Gland Pharma approach growth revival amid global trade uncertainties and cautious economic signals.

Gland Pharma's acquisition of Cenexi has hurt its margins, but Cenexi recently became EBITDA-positive, suggesting a possible turnaround.

Cenexi, Gland Pharma's European acquisition, has achieved EBITDA breakeven, but ongoing operational and structural challenges temper optimism for a full turnaround.

Gland Pharma's European acquisition, Cenexi, has turned EBITDA-positive, but faces ongoing operational challenges that continue to impact the parent company's overall financial performance.

Gland Pharma's Q1 profit surged nearly 50% due to stronger European sales and improved margins despite U.S. market challenges.

Gland Pharma's Q1 profit surged 50% due to core growth and successful turnaround of acquired French CDMO Cenexi.

Gland Pharma saw a 50% PAT increase and its Cenexi subsidiary reached EBITDA breakeven in Q1, alongside a 7% revenue growth.

Cenexi, Gland Pharma's subsidiary, faced regulatory observations in France but submitted an accepted CAPA plan to address issues without disrupting manufacturing.

Cenexi, Gland Pharma's subsidiary, received 11 regulatory observations from the French ANSM, submitted a corrective plan, and manufacturing continues unaffected.

Cenexi received 11 GMP-related observations from the French regulator but will continue operations while implementing corrective actions.

Gland Pharma's Q4 performance is expected to be stable, supported by strong US sales and new launches, with Cenexi showing signs of recovery despite ongoing risks.

Gland Pharma International PTE will acquire 100% of Cenexi and its holding entities, pending regulatory approval, while Gland Pharma experienced a decline in Q2 FY23 net profit and sales.

Cenexi, a European sterile pharmaceutical manufacturer, was acquired by Indian Gland Pharma, controlled by Chinese Fosun, in a €230 million deal.